Highlight the significance of genetic evolution of H5N1 avian flu

Chinese Medical Journal

Volumn 119, Issue 17, 2006, Pages 1458-1464

  Lu, Jia Hai ^a   Zhang, Ding Mei ^a   Wang, Guo Ling ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Avian influenza; H5N1 virus; Human transmission; Molecular Evolution; Zoonosis

Indexed keywords

ADENOVIRUS VECTOR; AMANTADINE; ANTIVIRUS AGENT; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; INFLUENZA VACCINE; MUSCARINIC M2 RECEPTOR ANTAGONIST; OSELTAMIVIR; RIMANTADINE; SIALIDASE INHIBITOR; VIRUS RNA; ZANAMIVIR;

ANTIBODY RESPONSE; ARTICLE; AVIAN INFLUENZA; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG MEGADOSE; DRUG TOLERABILITY; EPIDEMIC; HUMAN; IMMUNE RESPONSE; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INFLUENZA VIRUS C; MOLECULAR EVOLUTION; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; RNA SEQUENCE; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SPECIES DIFFERENCE; STRAIN DIFFERENCE; TREATMENT FAILURE; VACCINE PRODUCTION; VIRUS CELL INTERACTION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS VIRULENCE; ZOONOSIS;

EID: 33748620302     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200609010-00009     Document Type: Article

References (49)

1. WHO (World Health Orgnization). Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. (Accessed April 26, 2006 at: http://www.who.int/csr/disease/avian_influenza/country/ cases_table_2006_05_19/en/index.html.)
2. Jong MD, Hien TT. Avian influenza A (H5N1). J Clin Virol 2006;35: 2-13.
3. Taubenberger JK, Reid AH, Lourens RM, Wang R, Jin G, Fanning TG. Characterization of the 1918 influenza virus polymerase genes. Nature 2005; 437:889-893.
4. Fauci AS. Emerging and re-emerging infectious diseases: influenza as a prototype of the host-pathogen balancing act. Cell 2006; 124:.665-670.
5. Xu X, Subbarao, Cox NJ, Guo Y. Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. Virology 1999;261:15-19.
6. Guan Y, Shortridge KF, Krauss S, Webster RG. Molecular characterization of H9N2 influenza viruses; were they the donors of the "internal" genes of H5N1 viruses in Hong Kong? Proc Natl Acad Sci U S A 1999; 96: 9363-9367.
7. Hoffmann E, Stech J, Leneva I, Krauss S, Scholtissek C, Chin PS, et al. Characterization of the influenza A gene pool in avian species in southern China: was H6N1 a derivative or a precursor of H5N1? J Virol 2000; 74:6309-6315.
8. Govorkova EA, Rehg JE, Krauss S, Yen HL, Guan Y, Peiris M, et al. Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J Virol 2005; 79: 2191-2198.
9. Cauthen AN, Swayne DE, Schultz-Cherry S, Perdue ML, Suarez DL. Continued circulation in china of highly pathogenic avian influenza viruses encoding the hemagglutinin gene associated with the 1997 H5N1 outbreak in poultry and humans. J Virol 2000; 74: 6592-6599.
10. Webster RG, Guan Y, Peiris M, Walker D, Krauss S, Zhou NN, et al. Characterization of H5N1 influenza viruses that continue to circulate in geese in southeastern China. J Virol 2002; 76: 118-126.
11. Normile D. Evidence points to migratory birds in H5N1 spread. Science 2006; 311:1225.
12. Hulse-Post DJ, Sturm-Ramirez KM, Humberd J, Seiler P, Govorkova EA, Krauss S, et al. Role of domestic ducks in the propagation and biological evolution of highly pathogenic H5N1 influenza viruses in Asia. Proc Natl Acad Sci U S A 2005;102: 10682-10687.
13. Normile D. Ducks may magnify threat of avian flu virus. Science 2004; 306: 953.
14. Li KS, Guan Y, Wang J, Smith GJ, Xu KM, Duan L, et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 2004; 430: 209-213.
15. Chen H, Smith GJ, Li KS, Wang J, Fan XH, Rayner JM, et al. Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc Natl Acad Sci 2006; 103: 2845-2850.
16. Isoda N, Sakoda Y, Kishida N, Bai GR, Matsuda K, Umemura T, et al. Pathogenicity of a highly pathogenic avian influenza virus, A/chicken/ Yamaguchi/7/04 (H5N1) in different species of birds and mammals. Arch Virol 2006; 151: 1267-1279.
17. Russell CJ, Webster RG. The genesis of a pandemic influenza virus. Cell 2005;10:368-371.
18. Hulse DJ, Webster RG, Russell RJ, Perez DR. Molecular determinants within the surface proteins involved in the pathogenicity of H5N1 influenza viruses in chickens. J Virol 2004; 78: 9954-9964.
19. Lewis DB. Avian flu to human influenza. Annu Rev Med 2006; 57:139-154.
20. Goto H, Wells K, Takada, Kawaoka Y. Plasminogen-binding activity of neuraminidase determines the pathogenicity of influenza A virus. J Virol 2001;75: 9297-9301.
21. Russell CJ, Webster RG. The genesis of a pandemic influenza virus. Cell 2005; 10:368-371.
22. Chen H, Deng G, Li Z, Tian G, Li Y, Jiao P, et al. The evolution of H5N1 influenza viruses in ducks in southern China. Proc Natl Acad Sci U S A 2004; 101:10452-10457.
23. Hampton T. Avian flu researchers make strides. JAMA 2006; 295: 1107-1108.
24. Normile D. Genomic analysis hints at H5N1 pathogenicity. Science 2006;311: 457.
25. Krug RM. Clues to the virulence of H5N1 viruses in humans. Science 2006; 311:1562-1563.
26. Gabriel G, Dauber B, Wolff T, Planz O, Klenk HD, Stech J. The viral polymerase mediates adaptation of an avian influenza virus to a mammalian host. Proc Natl Acad Sci U S A 2005; 102:18590-18595.
27. Sturm-Ramirez KM, Ellis T, Bousfield B, Bissett L, Dyrting K, Rehg JE, et al. Reemerging H5N1 influenza viruses in Hong Kong in 2002 are highly pathogenic to ducks. J Virol 2004; 78:4892-4901.
28. Guan Y, Poon LL, Cheung CY, Ellis TM, Lim W, Lipatov AS, et al. H5N1 influenza: a protean pandemic threat. Proc Natl Aced Sci U S A 2004; 101: 8156-8161.
29. Matrosovich M, Zhou N, Kawaoka Y, Webster R. The surface glycoproteins of H5 influenza viruses isolated from humans, chickens, and wild aquatic birds have distinguishable properties. J Virol 1999; 73:1146-1155.
30. Ito T, Couceiro JN, Kelm S, Baum LG, Krauss S, Castrucci MR, et al. Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. J Virol 1998; 72: 7367-7373.
31. Yao Y, Mingay LJ, Mccauley JW, Barclay WS. Sequences in influenza A virus PB2 protein that determine productive infection for an avian influenza virus in mouse and human cell lines. J Virol 2001; 75: 5410-5415.
32. Vines A, Wells K, Matrosovich M, Castrucci MR, Ito T, Kawaoka Y. The role of influenza A virus hemagglutinin residues 226 and 228 in receptor specificity and host range restriction. J Virol 1998; 72:7626-7631.
33. Stevens J, Blixt O, Glaser L, Taubenberger JK, Palese P, Paulson JC, et al. Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J Mol Biol 2006; 355:1143-1155.
34. Kuiken T, Rimmelzwaan G, van Riel D, van Amerongen G, Baars M, Fouchier R, et al. Avian H5N1 influenza in cats. Science 2004;306:241.
35. Buxton Bridges C, Katz JM, Seto WH, Chan PK, Tsang D, Ho W, et al. Risk of influenza A (H5N1) infection among health care workers exposed to patients with influenza A (H5N1), Hong Kong. J Infect Dis 2000; 181:344-348.
36. Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, Puthavathana P, et al. Probable person-to-person transmission of avian influenza A (H5N1).N Engl J Med 2005;352:333-340.
37. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KH, et al. Isolation of drug-resistant H5N1 virus. Nature 2005; 437:1108.
38. Riedel S. Crossing the species barrier: the threat of an avian influenza pandemic. Proc (Bayl Univ Med Cent) 2006; 19:16-20.
39. Wood JM, Robertson JS. From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat Rev Microbiol 2004; 2: 842-847.
40. Horimoto T, Takada A, Fujii K, Goto H, Hatta M, Watanabe S, et al. The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate. Vaccine 2006; 24:3669-3676.
41. Cinti S, Chenoweth C, Monto AS. Preparing for pandemic influenza: should hospitals stockpile oseltamivir? Infect Control Hosp Epidemiol 2005; 26: 852-854.
42. Hoelscher MA, Garg S, Bangari DS, Belser JA, Lu X, Stephenson I, et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 2006; 367: 475-481.
43. Klaus Stohr. Avian influenza and pandemics - research needs and opportunities. N Engl J Med 2005; 352: 405-407.
44. Hay AJ, Zambon MC, Wolstenholme AJ, Skehel JJ, Smith MH. Molecular basis of resistance of influenza A viruses to amantadine. J Antimicrob Chemother 1986; 18 Suppl B: 19-29.
45. Scholtissek C, Quack G, Klenk HD, Webster RG. How to overcome resistance of influenza A viruses against adamantane derivatives. Antiviral Res 1998; 37: 83-95.
46. Ilyushina NA, Bovin NV, Webster RG, Govorkova EA. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 2006; 70: 121-131.
47. Moscona A. Oseltamivir resistance - disabling our influenza defenses. N Engl J Med 2005; 353:2633-2636.
48. de Jong MD, Thanh TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353:2667-2672.
49. Lu J, Guo Z, Pan X, Wang G, Zhang D, Li Y, et al. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab1) 2 in mice. Respir Res 2006; 7: 43.